文献速递瘢痕与激光

A型肉毒毒素注射治疗瘢痕的有效性:随机对照试验的系统综述与Meta分析

Effectiveness of Botulinum Toxin Type A Injection on Scars: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · Plast Reconstr Surg · 2022-09-19

该系统综述纳入21项随机对照试验,评估A型肉毒毒素(BoNT-A)治疗瘢痕的有效性。BoNT-A组温哥华瘢痕量表评分低于盐水组(SMD -0.73,95%CI -1.12至-0.35,p=0.0002),但高于类固醇组(SMD 0.85,95%CI 0.27至1.43,p=0.004)。作者认为BoNT-A治疗瘢痕比盐水更有效,但类固醇可能效力更高,可考虑作为不适合类固醇治疗患者的替代选择。

要点

  • BoNT-A组温哥华瘢痕量表评分低于盐水组(SMD -0.73,95%CI -1.12至-0.35,p=0.0002)。
  • BoNT-A组温哥华瘢痕量表评分高于类固醇组(SMD 0.85,95%CI 0.27至1.43,p=0.004)。
  • BoNT-A组瘢痕宽度较对照组显著缩短(SMD -1.11,95%CI -1.38至-0.83,p<0.00001)。

核心结论

  • BoNT-A治疗瘢痕比盐水更有效,但类固醇可能效力更高;因此,可考虑作为不适合类固醇治疗患者的替代选择。

研究设计与样本

  • 系统综述与Meta分析,纳入21项研究BoNT-A治疗瘢痕有效性的随机对照试验。
  • 提取温哥华瘢痕量表、Stony Brook瘢痕评估量表、外观评估视觉模拟量表、瘢痕疼痛评估视觉模拟量表和瘢痕宽度的均数与标准差进行亚组分析。

主要发现

  • BoNT-A组温哥华瘢痕量表评分低于盐水组(SMD -0.73,95%CI -1.12至-0.35,p=0.0002),但高于类固醇组(SMD 0.85,95%CI 0.27至1.43,p=0.004)。
  • BoNT-A组Stony Brook瘢痕评估量表等级高于盐水组(SMD 1.42,95%CI 0.83至2.00,p<0.00001)。
  • BoNT-A组外观评估视觉模拟量表评分高于盐水组(SMD 1.14,95%CI 0.69至1.60,p<0.00001)。
  • BoNT-A组疼痛评估视觉模拟量表评分低于类固醇组(SMD -2.57,95%CI -4.40至-0.74,p=0.006)。
  • BoNT-A组瘢痕宽度较对照组显著缩短(SMD -1.11,95%CI -1.38至-0.83,p<0.00001)。

关键数值与推荐

  • BoNT-A组温哥华瘢痕量表评分低于盐水组(SMD -0.73,95%CI -1.12至-0.35,p=0.0002)。
  • BoNT-A组温哥华瘢痕量表评分高于类固醇组(SMD 0.85,95%CI 0.27至1.43,p=0.004)。
  • BoNT-A组Stony Brook瘢痕评估量表等级高于盐水组(SMD 1.42,95%CI 0.83至2.00,p<0.00001)。
  • BoNT-A组外观评估视觉模拟量表评分高于盐水组(SMD 1.14,95%CI 0.69至1.60,p<0.00001)。
  • BoNT-A组疼痛评估视觉模拟量表评分低于类固醇组(SMD -2.57,95%CI -4.40至-0.74,p=0.006)。

临床怎么用

  • 作者认为BoNT-A治疗瘢痕比盐水更有效,但类固醇可能效力更高,可考虑作为不适合类固醇治疗患者的替代选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Scars can cause pain, long-term physical dysfunction, and psychological harm. Botulinum toxin type A (BoNT-A) is one treatment choice for scars, but further evidence is needed to confirm its efficacy. METHODS: This systematic review included randomized controlled trials that investigated the effectiveness of BoNT-A on scars. The mean and standard deviation for the Vancouver Scar Scale, Stony Brook Scar Evaluation Scale, visual analog scale for appearance evaluation, visual analog scale for scar pain evaluation, and scar width were extracted for subgroup analysis. RESULTS: Twenty-one randomized controlled trials were included. The BoNT-A group had a lower Vancouver Scar Scale score than the saline group (standardized mean difference, -0.73; 95 percent CI, -1.12 to -0.35; p = 0.0002) but a higher score than the steroid group (standardized mean difference, 0.85; 95 percent CI, 0.27 to 1.43; p = 0.004). The BoNT-A group exhibited a higher Stony Brook Scar Evaluation Scale grade than the saline group (standardized mean difference, 1.42; 95 percent CI, 0.83 to 2.00; p < 0.00001). The visual analog scale for appearance evaluation revealed higher scores in the BoNT-A group than in the saline group (standardized mean difference, 1.14; 95 percent CI, 0.69 to 1.60; p < 0.00001). As for pain evaluation, the BoNT-A group had a lower visual analog scale score than the steroid group (standardized mean difference, -2.57; 95 percent CI, -4.40 to -0.74; p = 0.006). Furthermore, scar width was significantly shorter in the BoNT-A group than in the control group (standardized mean difference, -1.11; 95 percent CI, -1.38 to -0.83; p < 0.00001). CONCLUSIONS: BoNT-A is more effective in treating scars than saline, although steroids may exhibit higher potency. Therefore, it can be considered an alternative in patients not amenable to steroid treatment. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Li MY, Chiu WK, Wang HJ, et al. Effectiveness of Botulinum Toxin Type A Injection on Scars: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Plast Reconstr Surg. 2022. PMID: 36112846. doi:10.1097/PRS.0000000000009742

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。